A clinical trial is evaluating the dopamine D2 and D3 receptor occupancy of SIPI6398, a novel investigational agent for schizophrenia.

A Phase 2a open-label trial evaluates the safety and antidepressant efficacy of inhaled mebufotenin (GH001), a rapid-acting 5-HT agonist, in adult patients with postpartum depression.

New pharmacogenomic testing is available to help explain individual variability in response to ADHD medications, offering a clinical tool for optimizing prescribing decisions.

This meta-analysis synthesizes current evidence on genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness, highlighting the role of pharmacogenomics in predicting this adverse effect.

A randomized crossover trial found that N-acetylcysteine, but not gabapentin, significantly reduced dorsal anterior cingulate cortex glutamate levels and heavy drinking days in patients with comorbid bipolar disorder and alcohol use disorder, supporting further mechanistic trials of glutamatergic modulation.

A randomized, double-blind, placebo-controlled trial evaluates the efficacy of cannabidiol for managing behavioral and psychological symptoms of vascular dementia.

This podcast episode reviews the neurobiology and therapeutic potential of neuromodulation (TMS/SAINT) and psychedelic-assisted therapies (psilocybin, MDMA, ibogaine, ayahuasca) for depression and PTSD, though it lacks specific clinical trial data or prescribing guidelines.

A completed clinical trial comparing the Reacor adaptive biofeedback system, escitalopram, and their combination for the treatment of anxiety disorders.

A meta-analysis identifies higher baseline OCD severity as a predictor of long-term response to deep brain stimulation, while concurrent antipsychotic and antidepressant use predicts poorer outcomes.

A review published in the Australian Journal of General Practice suggests limited benefit and increased health risks for antidepressant use beyond 12 months, recommending regular treatment reviews.

A feasibility trial suggests ketogenic dietary therapy is safe and may reduce core symptoms of anorexia nervosa in adults, offering a potential non-pharmacologic treatment option.

This systematic review of international guidelines identifies core components for early intervention in psychosis, emphasizing cautious antipsychotic use for clinical high-risk patients and structured pharmacological monitoring for first-episode psychosis.

A case report suggests spectral EEG-guided personalized TMS may reduce social anxiety symptoms and normalize EEG patterns, warranting further investigation as an adjunctive treatment.

This systematic review of fMRI studies identifies specific neural circuit alterations in PMDD, providing a mechanistic basis for the partial non-response to SSRIs and informing the development of novel therapeutic targets.

A study reveals that deep brain stimulation (DBS) remodels white matter pathways and alters neural networks, providing a biological mechanism for its efficacy in severe depression.

Axsome Therapeutics has settled with the last applicant to delay generic competition for the narcolepsy drug Sunosi until 2040, preserving market exclusivity.

An expert panel recommends regular review of psychotropic medications to optimize prescribing practices and patient safety.

The FDA issued a Complete Response Letter for CTx-1301, a potential new treatment for ADHD, indicating regulatory hurdles for this psychopharmacologic candidate.

Axsome Therapeutics has settled patent litigation for the narcolepsy drug Sunosi (solriamfetol), delaying generic competition until 2040 and securing market exclusivity while the company expands its indications to ADHD and depression.

A new study challenges the long-term efficacy of antidepressants for relapse prevention beyond 12 months, suggesting benefits may be overstated.

This retrospective study compares the clinical profiles and treatment outcomes of clozapine in adolescents with schizophrenia versus those with autism spectrum disorder, providing real-world evidence for its off-label use in severe ASD irritability.

A case register study reinforces lithium monotherapy as a first-line maintenance treatment for bipolar disorder, supporting its continued use for long-term pharmacological management.

A nationwide matched cohort study with co-twin comparison investigates the association between incident benzodiazepine and Z-drug use and the subsequent risk of developing alcohol- and drug-related problems.

This review synthesizes translational research on oxytocin therapy for schizophrenia negative symptoms, detailing its multi-target neural mechanisms and highlighting the need for precision psychiatry approaches to address clinical heterogeneity.

Preclinical study demonstrates that psilocybin reduces neuropathic pain behaviors in mice and enhances the analgesic effects of gabapentin, suggesting a potential mechanistic basis for psilocybin's role in pain modulation.

A double-blinded placebo-controlled study investigates the impact of psilocybin on subjective and objective time perception, contributing to the mechanistic understanding of psychedelic effects relevant to psychiatric treatment.

Early tapering from opioid agonist treatment (methadone or buprenorphine/naloxone) increases taper completion rates but significantly raises all-cause mortality risk compared to waiting 12-48 months.